AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00966550 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tomato
Description: Tomato with high carb/fat meal
Study NCT00966550 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-tomato
Description: Non-tomato with high carb/fat meal
Study NCT02207413 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influsplit Tetra™ vaccine produced by investigational process (IP)
Description: Influsplit Tetra™ vaccine using a new manufacturing process administered intramuscularly (IM) in the deltoid region of non-dominant arm (Dose 1) in Adults Group and in non-dominant deltoid or left anterolateral thigh (Dose 1) and dominant deltoid or right anterolateral (Dose 2 - unprimed subjects) in 6-35m and 3-17y Groups.
Study NCT02207413 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influsplit Tetra™ vaccine produced by licensed process (LP)
Description: Influsplit Tetra™ vaccine using a licensed manufacturing process administered IM in the deltoid region of non-dominant arm (Dose 1) in Adults Group and in non-dominant deltoid or left anterolateral thigh (Dose 1) and dominant deltoid or right anterolateral (Dose 2 - unprimed subjects) in 6-35m and 3-17y Groups.
Study NCT00532233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAX576
Study NCT03172026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc 300 mg
Description: FDA approved chemokine receptor (CCR5) inhibitor. Maraviroc will be started within two weeks of discharge from inpatient rehabilitation, which most often will occur from 4-6 weeks after stroke onset.
Study NCT03172026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation therapy
Description: All participants will have routine outpatient or home health physical and occupational therapy after inpatient discharge as prescribed by their physicians.~Each group will be contacted weekly by phone to help maintain interest in the trial, count the number of usual care physical and occupational therapy completed, assure use of the assigned medication, ask about possible adverse reactions, and to encourage them to be active. The coordinator will obtain this information and provide the feedback using a standard script and checklist. A unique aspect of this trial is a telerehabilitation component that aims to give feedback to all participants to practice with the affected arm and walk daily.
Study NCT03172026 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Rehabilitation therapy
Description: All participants will have routine outpatient or home health physical and occupational therapy after inpatient discharge as prescribed by their physicians.~Each group will be contacted weekly by phone to help maintain interest in the trial, count the number of usual care physical and occupational therapy completed, assure use of the assigned medication, ask about possible adverse reactions, and to encourage them to be active. The coordinator will obtain this information and provide the feedback using a standard script and checklist. A unique aspect of this trial is a telerehabilitation component that aims to give feedback to all participants to practice with the affected arm and walk daily.
Study NCT03172026 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 300 mg
Description: Matched placebo will be started within two weeks of discharge from inpatient rehabilitation, which most often will occur from 4-6 weeks after stroke onset.
Study NCT04036812 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Superficial cervical plexus block
Description: superficial cervical plexus nerve block will be performed under the guidance of ultrasound
Study NCT04036812 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: ultrasound guidance will be used to determine the location of superficial cervical plexus nerve. The puncture will also be performed by ultrasound guidance, covered with opaque infusion dressing but performed with infusion of 10 ml normal saline.
Study NCT00365274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV 750 mg/m\^2 day 1
Study NCT00365274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin hydrochloride
Description: Given 50 mg/m\^2 IV day 1
Study NCT00365274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given 1.4 mg/m\^2 IV
Study NCT00365274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 100 mg orally daily days 1 - 5
Study NCT00365274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-30
Description: 12 mg/kg weekly IV over 2 hours once weekly for 3 weeks.
Study NCT00514371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin
Description: High dose
Study NCT00514371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Mid dose, and low dose
Study NCT02085304 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gross total resection and Gliadel(R) wafers implanted
Description: Complete removal of tumor and implant of Gliadel(R) wafers that are small, dime-sized wafers designed to deliver the chemo drug, carmustine, directly into the cavity made when the brain tumor was removed.
Study NCT02085304 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gross total resection and Gliadel(R) wafers implanted
Description: Complete removal of tumor and implant of Gliadel(R) wafers that are small, dime-sized wafers designed to deliver the chemo drug, carmustine, directly into the cavity made when the brain tumor was removed.
Study NCT02085304 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: GammaKnife(R) stereotactic Radiosurgery
Description: GammaKnife® (GK) radiosurgery dose of 15 Gy in one fraction to the resection cavity margin
Study NCT02085304 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard fractionated radiation therapy
Description: standard fractionated RT of 60 Gy in 30 fractions (over approximately six weeks)
Study NCT02085304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: temozolomide 75 mg/m2 daily for 42 days, will be administered to all patients beginning within 24 hours of GK/RT initiation as is routine clinical care. There will be a one month drug holiday following the 42 days before adjuvant chemotherapy begins. Adjuvant temozolomide administered 5 days monthly at 150-200 mg/m2/day will be administered for 12 months as is routine clinical care.
Study NCT02085304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: temozolomide 75 mg/m2 daily for 42 days, will be administered to all patients beginning within 24 hours of GK/RT initiation as is routine clinical care. There will be a one month drug holiday following the 42 days before adjuvant chemotherapy begins. Adjuvant temozolomide administered 5 days monthly at 150-200 mg/m2/day will be administered for 12 months as is routine clinical care.
Study NCT02277808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 500mg Amikacine (Amukin®) diluted in 4mL NaCl (0,9%)
Study NCT02277808 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respirgard II
Study NCT02277808 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Isoneb®
Study NCT04152798 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic hiatal hernia repair with ProGrip™ mesh
Description: Suturing of the right and left diaphragmatic crura using 3 to 4 interrupted nonabsorbable stitches with additional reinforcement of crura repair with ProGrip™ mesh
Study NCT04152798 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic primary posterior crural repair
Description: Posterior cruroraphy will be performed with 3 to 4 interrupted non-absorbable sutures
Study NCT02105675 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cells DCVAC/PCa
Description: DCVAC/PCa is the experimental therapy added on to Docetaxel
Study NCT02105675 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel is Standard of Care First Line Chemotherapy
Study NCT01642108 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sitagliptin
Description: 50 mg once per day
Study NCT03704909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adrenaline
Description: i.v bolus of adrenaline 0.15µg/Kg rescue boluses of adrenaline 0.15µg/Kg
Study NCT03704909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Description: i.v bolus of Ephedrine 0.1mg/Kg rescue boluses of Ephedrine 0.1mg/Kg
Study NCT00348309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone Extended Release 2mg
Description: Rosiglitazone Extended Release 2mg OD
Study NCT00348309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone Extended Release 8mg
Description: Rosiglitazone Extended Release 8mg OD
Study NCT00348309 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00348309 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil (At least 6 months of ongoing donepezil therapy for Alzheimer's disease, with stable dosing for at least the last 2 months (and with no intent to change for the duration of the study).
Study NCT00348309 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Donepezil
Description: Donepezil (At least 6 months of ongoing donepezil therapy for Alzheimer's disease, with stable dosing for at least the last 2 months (and with no intent to change for the duration of the study).
Study NCT03580226 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT02439034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Paracetamol 1 g IV then 1 g 3 times a day IV or oral (PO)
Study NCT02439034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Paracetamol 1 g IV then 1 g 3 times a day IV or oral (PO)
Study NCT02439034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Description: Ketoprofen\* 100 mg (IV then PO) : Ketoprofen 100 mg IV 2 times a day or Ketoprofen LP 100 mg PO 2 times a day.
Study NCT03686475 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biodentine
Description: pulpotomy for primary molars , clinical and radiographic evaluation at 1,3,6 and 12month
Study NCT03686475 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MTA pulpotomy
Description: MTA pulpotomy
Study NCT01303926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin pemetrexed
Description: Cisplatin 75 mg / m2 d1 with Pemetrexed 500 mg / m2 d1 every 3 weeks for 6 cycles followed (in responding or stable patients) by Pemetrexed 500 mg / m2 every 3 weeks, until progression or unacceptable toxicity
Study NCT01303926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin paclitaxel bevacizumab
Description: Carboplatin AUC 6 d1 plus Paclitaxel 200 mg/m2 d1 and Bevacizumab 15 mg/kg every 3 weeks for 6 cycles followed in stable or responding patients by Bevacizumab 15 mg/kg every 3 weeks, until progression or unacceptable toxicity
Study NCT00458653 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell Tumor Fusion
Description: Post-Transplant (Groups A and B): Given under the skin every four weeks for three doses.~Pre-Transplant (Group B): Injected under the skin in upper part of leg or arm prior to stem cell collection for ASCT
Study NCT00967811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation E1 of L-PPDS
Description: Control of IOP compared to baseline for Formulation E1 of the experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.
Study NCT00967811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation E2 of L-PPDS
Description: Control of IOP compared to baseline for Formulation E2 of experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.
Study NCT02609529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Food
Description: Serum-derived bovine immunoglobulin protein isolate will be supplied by EnteraHealth. The product is manufactured in accordance with Good Manufacturing Practice (GMP) and U.S. Food and Drug Administration (FDA) guidelines for medical food ingredients (21 CFR Part 110). Serum-derived bovine immunoglobulin protein isolate (SBI) is generally recognized as safe (GRAS). The FDA has reviewed the safety dossier for SBI as a medical food product.
Study NCT02609529 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03244280 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MOB015B
Description: Topical formulation
Study NCT03187314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiation
Description: RT to 60 Gy, 5 x per week，for 6 weeks. Radiation begun the day after the first dose of SHR-1210
Study NCT03187314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 (200mg fixed dose every 2 weeks for 5 cycles) will be administered as an intravenous infusion over 60 minutes.
Study NCT04927858 — intervention group
Intervention type: DRUG
Intervention: Empagliflozin
Description: Empagliflozin
Study NCT00027846 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV or SC (5mcg/kg/day) start on Day 3 and continue until ANC >1500/μl given subcutaneously or intravenously.
Study NCT00027846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV (375 mg/m2/day) Day 1 given as an IV infusion over one hour. For patients with BSA \<0.45m2 the dose is 12.5 mg/kg/day.
Study NCT00027846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV (1000mg/m2/day) Day 1 and 2 given as an IV infusion over one hour following carboplatin administration. For patients with BSA\<0.45m2 the dose is 33mg/kg/day on Day 1 and 2.
Study NCT00027846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given orally (50 mg/m2/day) orally once daily on Days 1 through 21. For patients with BSA \< 0.45 m2, the dosage is 1.7 mg/kg/day on Days 1 through 21.
Study NCT00027846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV or orally (1.5mg/m2/day) (maximum dose 2 mg) Day 1 and 8 given as IV bolus. For patients with BSA\<0.45m2 the dose is 0.05mg/kg.
Study NCT00027846 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Given once daily 5 days a week for 6-6½ weeks
Study NCT00027846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Mesna (200mg/m2/dose) Day 1 and 2. For patients with BSA\<0.45m2 the dose is (7mg/kg/dose). Combine mesna (200mg/m2) with cyclophosphamide and administer intravenously over one hour followed by mesna (200mg/m2) in 375 cc/m2 D5-1/2NS and run intravenously over 3 hours at 125cc/m2/hr. After 3 hour mesna, administer mesna (200 mg/m2/dose) IV over 15 minutes at hour 5.
Study NCT00027846 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Study NCT01473108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY 94-8862) PEG solution
Description: 2.5, 5, 10, 20 mg polyethylene glycol (PEG) solution of BAY 94-8862
Study NCT01473108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY 94-8862) immediate release tablet
Description: 20 mg BAY 94-8862 administered as 2 x 10 mg IR tablets
Study NCT01473108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone (Inspra®)
Description: Single oral dose of 50 mg eplerenone
Study NCT01473108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo (solution/tablet) corresponding to BAY 94-8862 dose in respective dose step
Study NCT04135300 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Single dose intravenous injection of BBM-H901
Description: Single dose intravenous infusion of BBM-H901, an adeno-associated viral (AAV) vector designed to drive expression of the human factor IX (hFIX) transgene in liver. The dose of BBM-H901 will be 5x10'12 vg/Kg.
Study NCT03473821 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOTIFS
Description: o MOTor Imagery to Facilitate Sensorimotor re-learning (MOTIFS) is an individualized and physical activity-specific integrated model that includes aspects of both neuromuscular training, as used in rehabilitation practices, and Dynamic Motor Imagery (DMI). DMI is a form of mental training in which the participant images him-/herself performing a task from a first-person perspective in order to maximize functional equivalence to the task in question. This includes dynamic, physical movement, as well as mental imaging. The intervention provides a framework for designing individualized, physical activity-specific rehabilitation exercises for knee-injured people.
Study NCT03809260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin (part 1)
Description: 1\~4d: Metformin 1000 mg bid (Except for 500 mg after 1d lunch), 16d\~19d: Metformin 1000 mg bid (Except for 500 mg after 16d lunch).
Study NCT03809260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: 11d: Vancomycin 250 mg bid, 12\~17d: Vancomycin 500 mg bid
Study NCT03809260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin (part 2)
Description: 1\~4d: Metformin 1000 mg bid (Except for 500 mg after 1d lunch)
Study NCT02384096 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional single source programming
Description: Precision Spectra SCS System using conventional single source programming.
Study NCT02384096 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Precision Spectra SCS System advanced programming
Description: Precision Spectra SCS System using advanced programming
Study NCT06254794 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood flow restriction with Delfi Personalized Tourniquet System (PTS)
Description: Standard of care physical therapy exercises with the use of the Delfi PTS cuff
Study NCT06254794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: Standard of care physical therapy exercises
Study NCT06254794 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physical therapy
Description: Standard of care physical therapy exercises
Study NCT04297111 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: GanedenBC30 (Bacillus coagulans GBI-30, 6086) capsule made of 1 billion colony forming units (cfu). Description: pure cell mass of an L-(+) lactic acid-producing, gram-positive, spore-forming shaped bacterium that is aerobic to microaerophilic. Maltodextrin used as filler.
Study NCT04297111 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin capsule, no active ingredient
Study NCT05102773 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood and stool
Study NCT05102773 — intervention group
Intervention type: PROCEDURE
Intervention: Computed Tomography
Description: Undergo CT
Study NCT05102773 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT05102773 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study NCT05109949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10Mg Tab
Description: Daily morning dose per oral of Dapagliflozin 10 mg for 7 days
Study NCT05109949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 MG
Description: Daily morning dose per oral of Empagliflozine 25 mg for 7 days
Study NCT05109949 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily morning dose per oral of Calcined magnesite 500 mg for 7 days
Study NCT00821847 — intervention group
Intervention type: OTHER
Intervention: DEXA scan
Description: DEXA scan
Study NCT04095611 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SPAIRE
Description: To perform the hip surgery called hemiarthroplasty surgeons need to cut through some muscles to expose the hip joint and perform the partial replacement. Currently this often performed using a technique which involves cutting muscles and tendons from the side of the hip and this is called the lateral approach. SPAIRE is a modified technique that accesses the surgical area through a different route.
Study NCT04095611 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LATERAL
Description: surgery in adults with a displaced intracapsular hip fracture requiring hemiarthroplasty, the standard lateral approach.
Study NCT03759002 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging
Description: Imaging including Echocardiography for determining cardiac indices (ejection fraction, left ventricular mass index, strain rate, global longitudinal strain) and Doppler ultrasound for measuring carotid intima media thickness
Study NCT04221165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAiN - multimodal analgesia
Description: PAiN: Pregabalin, Acetaminophen, Naproxen, pantoprazole magnesium
Study NCT03759002 — intervention group
Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling will performed on all participants for measuring hematological parameters including MPV.